|
Indian pharma's digital transformation fuels emergence of new, high-demand careers
|
|
Nandita Vijayasimha, Bengaluru
December 24 , 2025
|
|
|
Indian pharma is in the midst of a digital transformation, as artificial intelligence, data analytics and automation take centrestage. This has transformed how companies research, manufacture and market medicines which is seen to create new, high-demand career opportunities.
Shiv Nath Ghosh, chief commercial officer, Professional Talent Solutions, Randstad India, said that pharma and healthcare sectors saw a year-on-year surge of more than 60% in job postings especially in roles linked to digital health, informatics and AI.
As a result, career paths are expanding beyond lab scientists and production staff into digital-pharma roles like data scientists in clinical-trial platforms, engineers validating computer systems, and AI specialists in drug discovery workflows. At Randstad India, we are seeing demand from clients for hybrid skill-sets, life-science domain knowledge coupled with digital fluency. For talent, this means that the ‘molecule to machine’ opens up exciting transitions. Companies which build this new workforce ahead of the curve will gain a strong competitive edge in innovation and operations, he added.
There is a deep-digital shift integrating AI, cloud-based lab information systems, digital compliance and analytics across R&D, manufacturing and supply-chain functions. The convergence of drug-discovery processes with digital technologies is reshaping pharma careers in India, said Ghosh.
By 2030, Indian pharma and biotech workforce will form a significant portion of total employment sector as digital and R&D expansion accelerates. What this means for jobs is significant as the classical path of ‘bench scientist to senior scientist to research head’ is being supplemented by new lanes like AI-driven biomarker scientists, cloud-platform engineers for clinical-data lakes, and digital-regulatory specialists managing real-time compliance.
We are working with clients to map these new roles and up-skill existing talent accordingly. For talent aspirants, this means embracing domain-adjacent skills. For example, a chemist learning computational biology tools, or a data-engineer gaining exposure in pharmacovigilance platforms. As drug discovery meets digital, companies who attract and retain this hybrid talent will redefine their innovation capability and stay ahead in tomorrow’s pharma ecosystem, he said,
There is also a significant shift in R&D hiring, where companies are no longer looking only for strong scientific depth but for talent that can transition from lab excellence to organisational leadership. As R&D diversifies into biologics, precision medicine, digital therapeutics and AI-enabled discovery, organisations increasingly need scientists who can manage cross-functional teams, and lead innovation at scale. This has led to the rise of hybrid roles such as ‘R&D Programme Leads,’ ‘Innovation Pipeline Managers,’ and ‘Translational Research Leaders,’ requiring both scientific fluency and business acumen. We see companies prioritising talent with competencies in project-management, data-driven decision-making, regulatory awareness, and stakeholder communication, alongside core technical skills, he said.
The ongoing pharma innovation spans mRNA platforms, complex injectables, specialty formulations, AI-enabled discovery, and advanced manufacturing requires a workforce that is far more specialised and future-ready. The challenge is not about the speed of innovation but whether the talent ecosystem can keep pace. Skills like biostatistics, computational biology, data engineering, GMP digitalisation and quality-by-design (QbD) are becoming essential. We are observing high demand for talent capable of operating in multidisciplinary environments where science, technology and compliance intersect. To match this, companies are investing in upskilling, collaborative research models, global leadership exposure, and specialised hiring strategies. Companies leading India’s next pharma growth cycle will be those that build strong, agile talent pipelines aligned to the complexity and ambition of their innovation agendas, said Ghosh.
|
|
|
|
|
|
|
|
TOPICS
|
The Food and Drug Administration (FDA), Maharashtra, has issued a public advisory urging citizens to report any misleadi ...
|
|
|
|
|